Physician profile
Jeffrey M Hadsall
NPI 1275641714
$1,382.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $193.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $263.96 | 2019-2020 | |
| Amgen INC. | $192.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $183.15 | 2019-2020 | |
| Amarin Pharma, INC. | $133.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $72.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $62.02 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.15 | 2019-2020 | |
| Abbvie INC. | $23.08 | 2020 | |
| Lundbeck LLC | $19.78 | 2019 | |
| Shire North American Group INC | $17.50 | 2019 | |
| Daiichi Sankyo INC. | $14.67 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.54 | 2019 | |
| Lilly USA, LLC | $14.37 | 2019 | |
| Allergan, INC. | $14.04 | 2019 | |
| Merck Sharp & Dohme LLC | $12.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hadsall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.